Embedded deep in any conference database of abstracts are often important findings, which tend to be overlooked by many observers in the rush to focus on the more obvious candidates.
Time to scale the cliff on a previously little known and undruggable target!
This preview and accompanying thought leader interview explores one such underrated avenue of research.
There is a lot to be said when we have clear signals from our knowledge of the underlying biology in front of us because they inform where therapeutic intervention should be both rational and fruitful.
Is this actually the case in practice?
We dug deeper to find out what’s really happening…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting together with our latest KOL interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Time for some reflection
Before we get to the World Congress in Lung Cancer (WCLC) taking place this weekend, I want to take a moment to reflect on some of the things we have learn over the last few weeks.
It’s time for a reader mailbag as we answer reader questions on the recent MYC mini-series, as well as covering bromodomain inhibitors (what’s going on there?) and discuss a new PROTAC compound in early development that looks quite interesting.
We also explain why that is the case…
To learn more from out latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.